A 70-year-old woman previously exposed to hyaluronidase during ophthalmic surgery had excision of hypertrophic bulbar conjunctival tissue in the right eye. Hyaluronidase was added to the peribulbar anesthetic agent. Five days postoperatively, the patient presented with proptosis in the right eye, extraocular muscle restriction, and decreased visual acuity. She was apyrexial with a normal white cell count; computed tomography of the orbits showed a diffuse increase in soft tissue density. Clinical features were unchanged after 24 hours of intravenous antibiotics, but subsequent administration of high-dose oral steroids led to clinical improvement.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcrs.2003.08.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative Assessment of the Allergenicity of Hyaluronidases from (Pol d 2), (Ves v 2), and Venom (Api m 2).
Toxins (Basel)
November 2024
Center of Allergy and Environment (ZAUM), Technical University of Munich, School of Medicine and Health & Helmholtz Munich, German Research Center for Environmental Health, 85764 Munich, Germany.
Article Synopsis
- * Key allergens evaluated include hyaluronidases from honey bee (Api m 2), European paper wasp (Pol d 2), and yellow jackets (Ves v 2.0101 and Ves v 2.0201), with sensitization rates among patients varying significantly.
- * Results show that individuals primarily sensitized to Api m 2 have minimal cross-reactivity with other venoms, while those sensitized to other allergens may react to Api m 2, emphasizing the importance of identifying the primary allergen for effective
Granulomatous Reaction to Lip Filler in a Patient with Ankylosing Spondylitis: A Case Report.
Cureus
October 2024
Dermatology, Baylor College of Medicine, Houston, USA.
Article Synopsis
- The popularity of minimally invasive cosmetic treatments, especially lip augmentation, has surged in recent years, with dermatologists providing safe and evidence-based options.
- Various lip fillers are available and have been extensively studied for safety; however, there's limited data on their effects in patients with autoimmune diseases.
- A specific case of a granulomatous delayed hypersensitivity reaction to hyaluronic acid filler in a patient with ankylosing spondylitis was successfully treated with hyaluronidase, emphasizing the need for awareness of such reactions and effective treatment options.
SARS-CoV-2 infection induces hyaluronan production and hyaluronan levels in COVID-19 patients relate to morbidity and long-term lung impairment: a prospective cohort study.
mBio
October 2024
Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
We previously demonstrated that the lungs of deceased COVID-19 patients were filled with a clear hydrogel consisting of hyaluronan (HA). In this translational study, we investigated the role of HA at all stages of COVID-19 disease to map the consequences of elevated HA on morbidity and identify the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced HA production. A reduced alveolar surface area was observed in the lungs of deceased COVID-19 patients compared to healthy controls, as visualized by a 3D rendering of lung morphology using light-sheet fluorescence microscopy.
View Article and Find Full Text PDFfSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study.
Allergy Asthma Clin Immunol
September 2024
Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Background: The safety, tolerability, and immunogenicity of hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% (dual-vial unit of human immunoglobulin 10% and recombinant human hyaluronidase [rHuPH20]) were assessed in children with primary immunodeficiency diseases (PIDs).
Methods: This phase 4, post-authorization, prospective, interventional, multicenter study (NCT03116347) conducted in the European Economic Area, enrolled patients aged 2 to < 18 years with a documented PID diagnosis who had received immunoglobulin therapy for ≥ 3 months before enrollment. New fSCIG 10% starters underwent fSCIG 10% dose ramp-up for ≤ 6 weeks (epoch 1) before receiving fSCIG 10% for ≤ 3 years (epoch 2); patients pretreated with fSCIG 10% entered epoch 2 directly.
Facilitated subcutaneous immunoglobulin (fSCIG) 10% is an immunoglobulin replacement therapy that utilizes recombinant human hyaluronidase (rHuPH20) to enhance immunoglobulin dispersion and absorption, allowing for longer treatment intervals similar to intravenous immunoglobulin (up to once monthly). fSCIG 10% is indicated in the USA for treating adults and children aged ≥ 2 years with primary immunodeficiency diseases (PIDs). This prospective, non-interventional, open-label, multicenter, post-authorization safety study (NCT02593188) was conducted in the USA from November 2015 to October 2021 to assess the long-term safety of fSCIG 10% in routine clinical practice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!